A Study of the Effects of Ranolazine Using Automated Quantitative Analysis of Serial Myocardial Perfusion Images
Rajesh Venkataraman, MD, MPH*,*,
Luiz Belardinelli, MD ,
Brent Blackburn, PhD,
Jaekyeong Heo, MD*,
Ami E. Iskandrian, MD*
* Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
Gilead Sciences Inc., Foster City, California
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Change in Exercise Treadmill Times
Change in exercise treadmill times (in seconds) before and after ranolazine therapy. The mean and SD values before and after treatment are shown.
|
|
View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Change in Quantitative Myocardial Perfusion Variables
Changes in summed stress score (SSS), summed rest score (SRS), and summed difference score (SDS) (top rows) and changes in total, fixed (scar), and reversible (ischemia) defect size by polar maps (bottom rows). The mean ± SD values are shown in each panel.
|
|
View larger version (55K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Representative Example of Improvement in Myocardial Perfusion by Single-Photon Emission Computed Tomography
A representative example of exercise myocardial perfusion imaging before and after ranolazine treatment showing quantitative improvement in myocardial perfusion in polar maps. Radionuclide injection was performed at a peak heart rate of 142 beats/min in both tests. The raw images during stress before ranolazine (A, top panel), stress after ranolazine (B, middle panel), and at rest (C, bottom panel) are shown. Each panel shows serial slices from the apex to the base in the short-axis projection and 1 slice at mid left ventricular level in the vertical and horizontal long-axis projections. The perfusion defect size decreased from 25% to 11% of left ventricular myocardium (14% absolute reduction) by polar maps, and the improvement is also visible by visual analysis of the images.
|
|
|
